Hologic, Inc. (NASDAQ:HOLX) – Analysts at Leerink Swann dropped their FY2018 earnings per share (EPS) estimates for shares of Hologic in a research note issued to investors on Thursday. Leerink Swann analyst R. Newitter now expects that the medical equipment provider will earn $2.17 per share for the year, down from their previous forecast of $2.27. Leerink Swann also issued estimates for Hologic’s FY2019 earnings at $2.45 EPS.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. During the same period in the prior year, the company earned $0.51 earnings per share. The business’s quarterly revenue was up 12.4% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: “FY2018 EPS Estimates for Hologic, Inc. Reduced by Analyst (HOLX)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/07/fy2018-eps-estimates-for-hologic-inc-reduced-by-analyst-holx.html.

Several other brokerages also recently commented on HOLX. Zacks Investment Research downgraded shares of Hologic from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Royal Bank Of Canada reduced their target price on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a report on Thursday. Deutsche Bank AG reduced their target price on shares of Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a report on Thursday. Stifel Nicolaus lifted their target price on shares of Hologic from $45.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, May 11th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $51.00 target price on shares of Hologic in a report on Friday, July 14th. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $48.64.

Hologic (NASDAQ:HOLX) opened at 39.25 on Monday. The firm has a market cap of $11.01 billion, a price-to-earnings ratio of 14.62 and a beta of 0.90. Hologic has a 12 month low of $35.15 and a 12 month high of $46.80. The stock’s 50 day moving average is $45.06 and its 200-day moving average is $42.98.

A number of hedge funds have recently bought and sold shares of HOLX. State Street Corp boosted its position in shares of Hologic by 1.5% in the first quarter. State Street Corp now owns 12,710,718 shares of the medical equipment provider’s stock valued at $540,846,000 after buying an additional 189,572 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock valued at $172,363,000 after buying an additional 3,269,503 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Hologic by 6.6% in the second quarter. Bank of Montreal Can now owns 3,418,319 shares of the medical equipment provider’s stock valued at $155,123,000 after buying an additional 211,550 shares during the last quarter. American Century Companies Inc. boosted its position in shares of Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock valued at $134,668,000 after buying an additional 2,204,085 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Hologic by 6.4% in the first quarter. Geode Capital Management LLC now owns 3,116,366 shares of the medical equipment provider’s stock valued at $132,440,000 after buying an additional 186,854 shares during the last quarter. 94.46% of the stock is owned by hedge funds and other institutional investors.

In other Hologic news, insider Peter J. Valenti III sold 10,005 shares of the business’s stock in a transaction dated Tuesday, May 30th. The shares were sold at an average price of $43.44, for a total value of $434,617.20. Following the completion of the sale, the insider now owns 20,994 shares of the company’s stock, valued at approximately $911,979.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Karleen Marie Oberton sold 4,704 shares of the business’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $45.19, for a total transaction of $212,573.76. The disclosure for this sale can be found here. Insiders sold a total of 63,562 shares of company stock valued at $2,802,013 in the last three months. Insiders own 0.79% of the company’s stock.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.